🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The end to a very well organized meeting!IACH. Much thanks to the @TheIACH co-chairs Mohamad Mohty Arnon Nagler and #COLYM co-chairs Mohamed Kharfan-Dabaja, MD, MBA Mehdi Hamadani, MD Stefano Luminari, MD Anna Sureda for the opportunity to present, learn and meet colleagues!!

AGAVE 201 out in NEJM. Remarkable efficacy of axatilimab (blocking CSF1R) in chronic #GvHD. I have some phenomenal response on trial. -Look for puffy eyes - Artifact elevation of AST/ALT/amylase/lipase due to inhibition of kupffer cells Saurabh Chhabra nejm.org/doi/abs/10.105…

Nivo+AVD led to longer progression-free survival than standard BV+AVD in adolescents & adults with stage III or IV advanced-stage classic Hodgkin lymphoma & had a better side-effect profile. Results of SWOG Cancer Research Network Children’s Oncology Group S1826 in NEJM. Jonathan Friedberg National Cancer Institute nejm.org/doi/10.1056/NE…

Outcomes post-CAR R/R MCL #ASH24: - 306 pts, 34% had POD after CAR (88% brexu-cel), 60% TP53mut at POD - median time from CAR to POD = 6 mos - post-CAR: mPFS 2.3 mos, worse if TP53mut - ORR after CAR best with BiTEs (60%) Dismal outcomes, need to study post-CAR strategies. #lymsm

Super proud of Yenny Moreno for doing a great job at presenting our multi center data for #alloHCT in #TCL ASH #ASH24

ASTCT Committee on Practice Guidelines Session: Madiha Iqbal MD presenting Follicular Lymphoma HCT and CT Guidelines #tandem2025 #lymsm

Engaging discussion with ⁦Dr. Alfredo Quiñones-Hinojosa⁩ at our ⁦Mayo Clinic Kern Scholars Program⁩ retreat today! ⁦Aaron Spaulding⁩ ⁦Gustavo Cortes-Puentes, M.D.⁩ ⁦Yan Bi, MD, PhD⁩ ⁦Victor Chedid, MD⁩ ⁦Annie Rusk⁩ ⁦Madiha Iqbal MD⁩ ⁦Mazie Tsang, MD, MAS, MS⁩ ⁦June Tome⁩ ⁦

📣We invite you to join the upcoming webinar by IACH: Management of Mantle Cell Lymphoma: an Update 🎙️Speaker: Madiha Iqbal 🗓️Monday, March 10 2025 ⏲️6PM CET Register for FREE bit.ly/4ks2jJB Mohamad Mohty Madiha Iqbal MD

The largest experience of autologous hematopoietic cell transplantation in 1700 patients with autoimmune diseases, in the outpatient setting, using the “Mexican method”. “Yes, it can be done” “Si se puede”Bone Marrow Transplantation Guillermo J. Ruiz-Argüelles David Gómez-Almaguer Andres Gomez

📣Join us at the 34th ANNUAL Mayo Clinic Comprehensive Cancer Center Florida #Hematology/#Oncology Reviews at Amelia Island #RitzCarlton (July 2025). Comprehensive #CME #Practical (in-person & virtual) Conference, with AMAZING speakers from Mayo Clinic & other GREAT centers. 👇🏼 tinyurl.com/56tmx6j7

Kicking off Aggressive NHL controversies Tim Fenske #HemOncPulse

Thank you for the invitation Mehdi Hamadani, MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Naval Daver, M.D.. Throughly enjoyed the thoughtful discussions.

Has the honor of participating in the inaugural @bmtctn Next Generation Scholar Program meeting #bmtsm

Excited to share findings from the multicenter ACCESS trial, supported by CIBMTR & NMDP . PTCy-based GVHD prophylaxis improved survival after MMUD HCT. Grateful for this collaboration advancing equitable transplant access. #ADonorForAll ascopubs.org/doi/10.1200/JC…

Great overview of emerging novel strategies in LBCL by Jason Westin, MD International Conference on Malignant Lymphoma #18ICML

Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by David Russler-Germain, MD/PhD at #18icml International Conference on Malignant Lymphoma, now available online in Cancer Cell. #lmsm WashU Medicine MD Anderson Cancer Center. cell.com/cancer-cell/fu…

Resection + RT improves PFS vs observation alone (90% vs 65%) for NLPHL presented by Jamie Flerlage #ICML18 GLOW: Global nLPHL One Working Group

RWE: Similar outcomes in older adults w bispecific treatment in LBCL with tolerable toxicity profile presented by Swetha Kambhampati for #CUBIC consortium #ICML2025 Ajay Major, MD, MBA City of Hope MD Anderson Cancer Center Women in Lymphoma - [email protected]

No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks no driving. #lymsm #tcellrx #mmsm fda.gov/vaccines-blood…

🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 nature.com/articles/s4159… PDF: rdcu.be/ewqLH